VetDC announces commercial launch of canine lymphoma drug

Tuesday April 4, 2017

FORT COLLINS (InnovatioNews, Terry Opgenorth) — VetDC, Inc., a veterinary cancer therapeutics company, announced that TANOVEA®-CA1 is now commercially available in the U.S. for purchase by licensed veterinarians.

TANOVEA-CA1 was recently granted conditional approval by the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM), making TANOVEA-CA1 the first and only new animal drug indicated for the treatment of lymphoma in dogs, the company said.

“VetDC stands out among an elite group of pure-play animal health startups that have advanced a novel program from development through commercialization,” said Dr. Terry Opgenorth, VP of CSU Ventures and VetDC co-founder.

“We believe TANOVEA-CA1 represents a significant breakthrough in the rapidly evolving field of veterinary oncology.”

“We are ecstatic to hear the news of TANOVEA-CA1’s commercial availability,” said Dr. Craig Clifford, a board-certified veterinary oncologist and clinical investigator at Hope Veterinary Specialists in Malvern, PA.

“Based on our first-hand experience as part of a robust clinical trials program, we believe TANOVEA-CA1 has the potential to become a cornerstone for the treatment of lymphoma in dogs.”

VetDC said TANOVEA-CA1 (rabacfosadine for injection) is a novel small molecule drug designed to preferentially target and attack rapidly dividing cancer cells implicated in lymphoma.

TANOVEA-CA1 has demonstrated anti-tumor activity in both naïve and relapsed canine lymphoma cases, with a generally well-tolerated safety profile, the company said.

TANOVEA-CA1 is administered intravenously every three weeks for up to five doses.

VetDC said TANOVEA-CA1 is conditionally approved by the FDA for the treatment of canine lymphoma pending a full demonstration of effectiveness.

For additional prescribing, safety and ordering information, visit tanovea.com.

This release was originally published on InnovatioNews on April 04, 2017. You can read the full article here.

0 Comments

Please provide us with the following before posting a comment